NMRA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.140

Open

2.090

VWAP

2.06

Vol

765.84K

Mkt Cap

371.36M

Low

2.005

Amount

1.58M

EV/EBITDA(TTM)

--

Total Shares

182.04M

EV

250.65M

EV/OCF(TTM)

--

P/S(TTM)

--

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Show More

Events Timeline

(ET)

2026-03-30

16:40:00

Major Averages Close Mixed as Oil Prices Continue to Rise

2026-03-30

12:10:00

Major U.S. Indices Rise as Oil Prices Surpass $100

2026-03-30

07:00:00

Neumora Reports $182.5M Cash in 2025, Advances Alzheimer's Therapy

2026-01-05 (ET)

2026-01-05

06:40:00

Neumora Therapeutics NMRA-511 Alzheimer's Study Shows Positive Results

2026-01-05

06:40:00

Neumora Therapeutics Updates Pipeline and Anticipates 2026 Milestones

News

Newsfilter

04-06Newsfilter

Neumora Therapeutics to Participate in Healthcare Conference

Globenewswire

04-01Globenewswire

Schall Law Firm Investigates Neumora Securities Violations

Yahoo Finance

03-31Yahoo Finance

Neumora Therapeutics Reports Positive Phase Ib Results for Alzheimer's Treatment

seekingalpha

03-30seekingalpha

Neumora Therapeutics Reports Q4 Earnings Miss and Financial Guidance

Globenewswire

03-25Globenewswire

Schall Law Firm Investigates Neumora Therapeutics for Securities Violations

Benzinga

NMRA-511 Shows Promising Results in Alzheimer's Agitation

8 Analyst Rating

Wall Street analysts forecast NMRA stock price to rise

5 Buy

2 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

9.33

High

18.00

Current: 0.000

Low

3.00

Averages

9.33

High

18.00

William Blair

Myles Minter

Market Perform

to

Outperform

upgrade

$7.62

AI Analysis

2026-02-17

Reason

William Blair

Myles Minter

Price Target

$7.62

AI Analysis

2026-02-17

upgrade

Market Perform

to

Outperform

Reason

William Blair analyst Myles Minter upgraded Neumora Therapeutics to Outperform from Market Perform with a net present value estimate of $7.62 per share. The firm increased its probability of success for NMRA-511 in Alzheimer's disease agitation to 35% after Neumora presented data from its Phase Ib study. The study showed meaningful reductions in the Cohen-Mansfield Agitation Inventory endpoint, the analyst tells investors in a research note. Blair continues to view Alzheimer's disease agitation as a blockbuster market opportunity with peak U.S. NMRA-511 sales of $1.8B "using conservative assumptions."

Mizuho

Outperform

maintain

$5 -> $6

2026-01-06

Reason

Mizuho

Price Target

$5 -> $6

2026-01-06

maintain

Outperform

Reason

Mizuho raised the firm's price target on Neumora Therapeutics to $6 from $5 and keeps an Outperform rating on the shares after the company made several announcements, highlighted by positive Phase 1b signal-seeking results for NMRA-511 in Alzheimer's disease agitation. Better results seen in a pre-specified subset of AD patients with elevated anxiety is "an encouraging finding," the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NMRA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Neumora Therapeutics Inc (NMRA.O) is 0.00, compared to its 5-year average forward P/E of -4.80. For a more detailed relative valuation and DCF analysis to assess Neumora Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.80

Current PE

0.00

Overvalued PE

-1.18

Undervalued PE

-8.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.58

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.23

Undervalued EV/EBITDA

-6.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

8.47

Current PS

72.54

Overvalued PS

33.49

Undervalued PS

-16.55

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best stocks under $5 to buy today

Intellectia · 10 candidates

Price: $0.50 - $5.00Market Cap Category: small, micro, nanoRsi Category: moderate, overboughtRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Week Price Change Pct: $3.00 - $50.00Monthly Average Dollar Volume: >= 750,000

Ticker

Name

Market Cap$

VivoPower International PLC

35.43M

Immunic Inc

109.76M

Neumora Therapeutics Inc

543.80M

Datavault AI Inc

459.29M

Grupo Televisa SAB

1.77B

Knightscope Inc

46.38M

small cap under $2

Intellectia · 1 candidates

Ticker

Name

Market Cap$

Neumora Therapeutics Inc

331.38M

Whales Holding NMRA

SoftBank Group Corp.

Wellcome Trust, Investment Division

ICONIQ Capital, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Neumora Therapeutics Inc (NMRA) stock price today?

The current price of NMRA is 2.04 USD — it has decreased -1.92

What is Neumora Therapeutics Inc (NMRA)'s business?

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

What is the price predicton of NMRA Stock?

Wall Street analysts forecast NMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMRA is9.33 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Neumora Therapeutics Inc (NMRA)'s revenue for the last quarter?

Neumora Therapeutics Inc revenue for the last quarter amounts to -58.48M USD, decreased -7.06

What is Neumora Therapeutics Inc (NMRA)'s earnings per share (EPS) for the last quarter?

Neumora Therapeutics Inc. EPS for the last quarter amounts to -47955000.00 USD, decreased -83.15

How many employees does Neumora Therapeutics Inc (NMRA). have?

Neumora Therapeutics Inc (NMRA) has 96 emplpoyees as of April 12 2026.

What is Neumora Therapeutics Inc (NMRA) market cap?

Today NMRA has the market capitalization of 371.36M USD.